Angela Walsh
SVP Finance and Treasurer, Vireos Therapeutics, Inc.
Replay available
Virios Therapeutics, Inc. (VIRI) Q3 2022 Earnings Call
Virios Therapeutics, Inc. (NASDAQ: VIRI) Q3 2022 earnings conference call, held 2022-11-14. Replay captured from the company's public earnings webcast.
Hosted by
Featured presenters
Richard Hanke
Analyst, Zax
Sean Lee
Analyst, HC Wainwright
Dr. R. Michael Gendro
Chief Medical Officer, Vireos Therapeutics, Inc.
Greg Duncan
Chief Executive Officer, Vireos Therapeutics, Inc.
Ralph Goswald
Senior Vice President of Operations, Vireos Therapeutics, Inc.
Investor webinar replay
Watch the replay and follow the connected company analysis, news, and investor updates for Dogwood Therapeutics, Inc..
Replay transcript excerpt
WEBVTT 00:00:00.009 -- 00:00:02.871 Good morning ladies and gentlemen, and thank you for your patience. 00:00:02.871 -- 00:00:05.973 This morning's conference call will begin soon. 00:00:05.973 -- 00:00:10.136 Please remain connected at this time. And once again, thank you for your patience. 00:00:10.136 -- 00:00:13.938 This morning's conference call will begin shortly. 00:00:26.343 -- 00:00:28.843 Thank you. 00:00:54.869 -- 00:00:57.109 Thank you. 00:01:22.374 -- 00:01:24.444 © transcript 00:01:26.265 -- 00:01:28.265 Emily 00:01:29.566 -- 00:01:31.566 Beynon 00:01:51.786 -- 00:01:55.888 Good day and welcome to the Vireos Therapeutics, Inc. 00:01:55.888 -- 00:02:01.011 Q3 earnings update. At this time, all participants have 00:02:01.011 -- 00:02:06.034 been placed on a listen-only mode. The floor will be open for questions 00:02:06.034 -- 00:02:09.896 and comments after the company presentation. 00:02:09.896 -- 00:02:15.660 It is now my pleasure to turn to proceedings over to Angela Walsh, SVP 00:02:15.660 -- 00:02:19.942 Finance and Treasurer, Vireos Therapeutics, Inc. 00:02:19.942 -- 00:02:22.863 Angela, the floor is yours. 00:02:23.339 -- 00:02:27.882 Thank you. Good morning, everyone, and thank you for joining us on today's conference 00:02:27.882 -- 00:02:33.125 call. We are pleased to be with you today to discuss Vireo Therapeutics' third quarter 00:02:33.125 -- 00:02:38.508 financial results, as well as to provide a summary of our ongoing analysis 00:02:38.508 -- 00:02:43.511 of the results from our recently completed Phase IIb Fibromyalgia Trial, 00:02:43.511 -- 00:02:48.674 also known as the FORTRESS Study. Please note that our financial results press 00:02:48.674 -- 00:02:52.145 release is now available on our website. 00:02:52.145 -- 00:02:57.327 We'll sta...